<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(3)</volume><submitter>Rousseau JF</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.&lt;h4>Objective&lt;/h4>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.&lt;h4>Design, setting, and participants&lt;/h4>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.&lt;h4>Exposure&lt;/h4>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.&lt;h4>Main outcomes and measures&lt;/h4>The primary end point w</pubmed_abstract><journal>JAMA network open</journal><pagination>e250548</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904722</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.</pubmed_title><pmcid>PMC11904722</pmcid><pubmed_authors>Rousseau JF</pubmed_authors><pubmed_authors>Messe SR</pubmed_authors><pubmed_authors>Schwamm LH</pubmed_authors><pubmed_authors>Fonarow GC</pubmed_authors><pubmed_authors>Xian Y</pubmed_authors><pubmed_authors>Sheth KN</pubmed_authors><pubmed_authors>Silva GS</pubmed_authors><pubmed_authors>Alhanti B</pubmed_authors><pubmed_authors>Saver JL</pubmed_authors><pubmed_authors>Mac Grory B</pubmed_authors><pubmed_authors>Smith EE</pubmed_authors><pubmed_authors>Weber JM</pubmed_authors><pubmed_authors>Warach SJ</pubmed_authors><pubmed_authors>Mullen MT</pubmed_authors></additional><is_claimable>false</is_claimable><name>Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.</name><description>&lt;h4>Importance&lt;/h4>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.&lt;h4>Objective&lt;/h4>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.&lt;h4>Design, setting, and participants&lt;/h4>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.&lt;h4>Exposure&lt;/h4>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.&lt;h4>Main outcomes and measures&lt;/h4>The primary end point w</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-06-06T23:41:34.747Z</modification><creation>2025-04-22T07:25:23.806Z</creation></dates><accession>S-EPMC11904722</accession><cross_references><pubmed>40072434</pubmed><doi>10.1001/jamanetworkopen.2025.0548</doi></cross_references></HashMap>